A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness

被引:25
作者
Gandjour, Afschin [1 ]
Stock, Stephanie [1 ]
机构
[1] Univ Cologne, Inst Hlth Econ & Clin Epidemiol, Cologne, Germany
关键词
cost-effectiveness; costs; drugs; hypertension; decision modeling;
D O I
10.1016/j.healthpol.2007.01.003
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Almost 15 million Germans may suffer from untreated hypertension. The purpose of this paper is to estimate the cost-effectiveness of a national hypertension treatment program compared to no program. A Markov decision model from the perspective of the statutory health insurance (SHI) was built. All data were taken from secondary sources. The target population consists of hypertensive male and female patients at high or low risk for cardiovascular events at different age groups (40-49, 50-59, and 60-69 years). The analysis shows fairly moderate cost-effectiveness ratios even for low-risk groups (less than is an element of 12,000 per life year gained). In women at high risk antihypertensive treatment even leads to savings. This suggests that a national hypertension treatment program provides good value for money. Given the considerable costs of the program itself, any savings from avoiding long-term consequences of hypertension are likely to be offset, however. (c) 2007 Published by Elsevier Ireland Ltd.
引用
收藏
页码:257 / 267
页数:11
相关论文
共 57 条
[11]   A comprehensive league table of cost-utility ratios and a sub-table of "Panel-worthy" studies [J].
Chapman, RH ;
Stone, PW ;
Sandberg, EA ;
Bell, C ;
Neumann, PJ .
MEDICAL DECISION MAKING, 2000, 20 (04) :451-467
[12]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[13]  
*DIS MAN ASS AM, 2006, DMAA DEF DIS MAN
[14]  
FAHEY T, 2006, COCHRANE REV, V4
[15]   Predictors of new-onset kidney disease in a community-based population [J].
Fox, CS ;
Larson, MG ;
Leip, EP ;
Culleton, B ;
Wilson, PWF ;
Levy, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (07) :844-850
[16]   COST-EFFECTIVENESS OF WARFARIN AND ASPIRIN FOR PROPHYLAXIS OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL-FIBRILLATION [J].
GAGE, BF ;
CARDINALLI, AB ;
ALBERS, GW ;
OWENS, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (23) :1839-1845
[17]   How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing [J].
Gandjour, A ;
Lauterbach, KW .
MEDICAL DECISION MAKING, 2005, 25 (03) :341-347
[18]   At what time is a reduction of medical under- or overtreatment sensible? Treatment of acute depression as an example [J].
Gandjour, A ;
Lauterbach, KW .
PSYCHIATRISCHE PRAXIS, 2004, 31 (03) :157-162
[19]   When is it worth introducing a quality improvement program? A mathematical model [J].
Gandjour, A ;
Lauterbach, KW .
MEDICAL DECISION MAKING, 2003, 23 (06) :518-525
[20]   Factors associated with differences in antihypertensive drug treatment:: results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95 [J].
Gasse, C ;
Hense, HW ;
Stieber, J ;
Döring, A ;
Liese, AD ;
Heller, G ;
Keil, U .
SOZIAL-UND PRAVENTIVMEDIZIN, 2002, 47 (02) :128-139